Impetiginized Dyshidrotic Eczema
AbstractA 16 years old female patient, affected by atopic dermatitis and rhinoconjunctivitis allergica since childhood, requested a dermatologic consultation for lesions which had appeared after 3 months of local treatment with clobethasole propionate. The histological analysis confirmed the diagnosis of dyshidrotic eczema and the microbiological smears demonstrated a significant infection with Staphylococcus aureus. The risk of developing corticosteroidsâ€™ side-effects depends on the potency of the product, extended period of use and the volume of product applied. Clobetasol propionate is a group I- highly potent corticosteroid, which should be used for a maximum period of 2 weeks. Several authors have found that this agent has cumulative depot effect, persisting in the epidermis for 4 days after only one application. Taking together these observations, sustained by the clinical case presented above, we can conclude that the infectious risks associated with topical corticosteroid treatment must not be neglected, particularly since treated patients are fragile, and frequently have multiple well-known risk factors.
Plum Analytics Artifact Widget Block
Ambach A, Bonnekoh B, Gollnick H. Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic rhinoconjunctivitis allergica. J Allergy Clin Immunol. 2001;107(5):878-86. https://doi.org/10.1067/mai.2001.114240 PMid:11344356
Boughrara Z, Ingen-Housz-Oro S, Legrand P, Duong TA, Roujeau JC. Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids. Ann Dermatol Venereol. 2010;137(5):345-51. https://doi.org/10.1016/j.annder.2010.03.015 PMid:20470914
Abidi A, Ahmad F, Singh SK, Kumar A. Study of reservoir effect of clobetasol propionate cream in an experimental animal study using histamine-induced wheal suppresion test. Indian J. Dermatol. 2010; 55:329-33. https://doi.org/10.4103/0019-5154.74531 PMid:21430883 PMCid:PMC3051290
Del Rosso JQ. Topical corticosteroid application and the structural and functional integrity of the epidermal barrier. J Clin Aesthet Dermatol. 2013; 6(11): 20-27.
Boudhir H, Mael-Ainin M, Senouci K, Hassam B, Benzekri L. Kaposi's disease: an unusual side-effect of topical corticosteroids. Ann Dermatol Venereol. 2013;140(6-7):459-61. https://doi.org/10.1016/j.annder.2013.04.078 PMid:23773746
Tadicherla S, Ross K, Shenefelt PD, Fenshe NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009; 8:1093-105. PMid:20027937
All rights reserved.